Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple ascending dose study of TAK-438 in healthy Japanese males
NCT02123953Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of vonoprazan in acid peptic disorder (APD) (6 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Adverse Events (AE), Number of Participants With Potentially Clinically Significant Vital Sign Findings and 10 more. Started Oct 2008; status: completed.
02
Drugs
vonoprazan
03
Conditions
acid peptic disorder (APD)
Beyond the preview
Go deeper on NCT02123953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123953.